

Attorney Docket No.: 10082.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Kjærulff et al.

Confirmation No: 5518

Serial No.: 09/981,009

Group Art Unit: 1638

Filed: October 16, 2001

Examiner: P. Bui

For: Transgenic Plants

**RECEIVED**  
**CENTRAL FAX CENTER**

**MAY 25 2004**

**CERTIFICATE OF FACSIMILE TRANSMISSION**

Commissioner for Patents  
Washington, DC 20231

**OFFICIAL**

Sir:


I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

was sent to the United States Patent Office by telefax to the attention of Examiner P. Bui, fax number (703) 308-4242.

Respectfully submitted,

Date: October 24, 2003

  
Lourdes Ayala  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

Attorney Docket No.: 10082.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Kjaerulff et al.

Confirmation No: 5518

Serial No.: 09/981,009

Group Art Unit: 1638

Filed: October 16, 2001

Examiner: P. Bui

For: Transgenic Plants

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the Office Action mailed October 6, 2003 that made restriction requirement between three designated groups.

In response to this requirement, Applicants hereby elect with traverse the invention of Group I, i.e., claims 1-26. Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.


The basis for traverse is that there would not be a serious burden on the examiner if restriction were not required between Groups I and II.

Moreover, Applicants submit that claim 1 links the inventions of Groups I and II. Therefore, upon allowance of the linking claim, the restriction requirement as to the linked inventions should be withdrawn and all claims within the linked inventions should be examined in the instant application.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: October 24, 2003



Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

TRANSMISSION VERIFICATION REPORT

TIME : 10/24/2003 15:03  
NAME : NOUDZYMES NA  
FAX : 2128400221  
TEL : 2128400097

DATE, TIME	10/24 15:02
FAX NO./NAME	17033084242
DURATION	00:00:38
PAGE(S)	02
RESULT	OK
MODE	STANDARD
	ECM